Oculis Holding AG has signed an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics, ending their previous license agreement and associated royalties. The deal includes an upfront cash payment of $3.8 million and up to 2,050,000 Oculis shares, with closing expected by early 2027. This acquisition strengthens Oculis' position in neuro-ophthalmology, allowing it to fully control Privosegtor, a promising neuroprotective drug candidate advancing through key clinical trials for optic neuritis and multiple sclerosis. The move is expected to enhance Oculis' long-term value and development potential for Privosegtor and related assets.
XRP's price fell 10.5% within 24 hours, dropping from $1.01 on November 14 to $0.905 by November 15, 2026. The decline is unexplained as no official statements from Ripple or exchanges have been made, and no confirmed data from XRP ETFs or order book...
Ether (ETH), the second-largest cryptocurrency by market value, fell below the $1,800 mark to $1,790 at 1:07 a.m. ET on November 15, according to Binance spot pricing. This represents a decline of about 0.94% over the previous hour. The drop signals ...
A Hyperliquid account revealed an 88.88 Bitcoin long position using 20x leverage, currently showing about $375,100 in unrealized losses with an average entry price of $68,866. The position's return is reported at -123.44%, indicating significant down...
Uber Technologies is rated a Buy with a fair value of $136, offering nearly 98% upside from current prices despite a recent 10% decline in its share price. The investment thesis is based on expected 20% growth in gross bookings, improving non-GAAP op...
On November 15, Ether (ETH) experienced a larger price decline of 4.84%, falling to $1,806.59, compared to Bitcoin's (BTC) 3.13% drop to $64,837.80 over the same 24-hour period. Funding rates, which reflect trader sentiment in perpetual futures marke...
